【摘 要】 目的：观察利伐沙班对非瓣膜性房颤患者抗凝治疗的效果及安全性。方法：我院2018年1月-2018年12月收治的142例非瓣膜性房颤患者为本次研究对象，按照是否给予利伐沙班治疗将所有患者分为对照组(71例：华法林治疗)与实验组(71例：利伐沙班治疗)，比较两组患者预后情况。结果：实验组患者治疗72h后D-二聚体、凝血酶原时间、血小板以及血小板分布宽度等相关凝血数值均明显优于对照组，P<0.05。实验组患者不良反应发生率(5.63%)明显低于对照组，P<0.O5。结论：非瓣膜性房颤患者利伐沙班治疗效果明显优于华法林治疗。

    【关键词】 利伐沙班;非瓣膜性房颤;抗凝治疗;效果;安全性

    【中图分类号】R821.4+2 【文献标志码】A【文章编号】1005-0019(2019)12-076-01

    Abstract Objective：To observe the efficacy and safety of rivaroxaban in anticoagulant therapy for patients with nonvalvular atrial fibrillation. Methods： 142 patients with nvaf admitted to our hospital from January 2018 to December 2018 were included in this study. All patients were divided into control group (71 cases：warfarin treatment) and experimental group (71 cases：rivaroxaban treatment) according to whether they were given rivaroxaban treatment ......